{"id":46309,"date":"2022-07-19T13:01:57","date_gmt":"2022-07-19T11:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/"},"modified":"2022-07-19T13:01:57","modified_gmt":"2022-07-19T11:01:57","slug":"avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/","title":{"rendered":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases"},"content":{"rendered":"
\n

\nUPMC spinout advances novel viral vector technology<\/i><\/b>\n<\/p>\n

PITTSBURGH–(BUSINESS WIRE)–Avista Therapeutics<\/a>, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company today announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes.\n<\/p>\n

<\/a><\/p>\n

\nThe partnership aims to apply Avista\u2019s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche. Under the terms of the partnership, Roche has the right to evaluate and license novel capsids from Avista, and will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy programs using these novel capsids, which will be distinct from Avista\u2019s internal pipeline.\n<\/p>\n

\n\u201cWe are excited to enter into this collaboration with Roche, a global leader in health care,\u201d said Robert Lin, Ph.D., Chief Executive Officer of Avista Therapeutics. \u201cThis collaboration will complement our in-house pipeline and will accelerate the delivery of transformative therapies to patients.\u201d\n<\/p>\n

\nAvista will receive an upfront payment of $7.5 million and, if successful, is eligible to receive additional payments during the research phase of the partnership, as well as clinical and sales milestone payments and royalties for resulting products with a total potential deal value that may exceed $1 billion.\n<\/p>\n

\nBuilt on the research of leading experts in viral vector development and clinical ophthalmology, Avista was founded by Leah Byrne, Ph.D., Assistant Professor of Ophthalmology at the University of Pittsburgh School of Medicine, an expert in AAV vector generation, Jos\u00e9-Alain Sahel, M.D., Chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, who is known worldwide for his expertise in vision restoration techniques, and Paul Sieving, M.D., Ph.D., internationally recognized physician-scientist and former director of the National Eye Institute.\n<\/p>\n

\nAvista\u2019s computationally guided, in vivo<\/i> scAAVengr platform leverages a high-throughput approach with built-in quantitative validation of novel cell-specific AAVs, enabling the rapid translation of transformative gene therapies to the clinic for diseases impacting people\u2019s vision. The company will develop a proprietary pipeline built on a toolkit of AAV variants that can target gene delivery to individual retinal cell types.\n<\/p>\n

\n“Traditional therapies for retinal dystrophies address only symptoms and complications, neglecting the underlying biology of the diseases, and while current vector technologies hold promise, they have been greatly limited in their ability to target key cell types across the retina,\u201d added Dr. Lin, who is also a vice president at UPMC Enterprises, the innovation, venture capital and commercialization arm of UPMC. \u201cAvista was founded to solve this problem, and our innovative scAAVengr platform allows us to deliver gene therapy payloads through intravitreal injection to treat a full range of retinal diseases with reduced immunogenicity.\u201d\n<\/p>\n

\nAvista received $10 million in seed funding and years of foundational support from UPMC Enterprises, which invests in translational science with the potential to radically transform health care.\n<\/p>\n

\n\u201cUPMC is thrilled to support the launch of Avista, a team with unmatched expertise in AAV technology and clinical ophthalmology who are addressing a diverse group of blinding disorders that have a profound impact on patients\u2019 quality of life,\u201d said Jeanne Cunicelli, President of UPMC Enterprises. \u201cWe believe that Avista is uniquely positioned to address the high unmet medical need in inherited retinal diseases.\u201d\n<\/p>\n

\nAbout Avista Therapeutics<\/b>\n<\/p>\n

\nAvista Therapeutics\u2019 mission is to develop innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on patients’ quality of life. We leverage our computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors that target specific cell types using minimally invasive intravitreal delivery with reduced dosages. Our quantitative, in vivo-based approach and clinical ophthalmology expertise allow us to rapidly translate new gene therapies to the clinic.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAvista Therapeutics
\n
Chris Stern
\n
c.stern@avistatx.com<\/a><\/p>\n

MEDIA<\/b>
MacDougall Advisors
\n
Lauren Arnold
\n
larnold@macdougall.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

UPMC spinout advances novel viral vector technology PITTSBURGH–(BUSINESS WIRE)–Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company today announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46309","6":"format-standard","7":"category-industry"},"yoast_head":"\nAvista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"UPMC spinout advances novel viral vector technology PITTSBURGH–(BUSINESS WIRE)–Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company today announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-19T11:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220719005166\/en\/1516386\/21\/Avista_Logo_Full_Color_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases\",\"datePublished\":\"2022-07-19T11:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/\"},\"wordCount\":661,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005166\\\/en\\\/1516386\\\/21\\\/Avista_Logo_Full_Color_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/\",\"name\":\"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005166\\\/en\\\/1516386\\\/21\\\/Avista_Logo_Full_Color_RGB.jpg\",\"datePublished\":\"2022-07-19T11:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005166\\\/en\\\/1516386\\\/21\\\/Avista_Logo_Full_Color_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220719005166\\\/en\\\/1516386\\\/21\\\/Avista_Logo_Full_Color_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases - Pharma Trend","og_description":"UPMC spinout advances novel viral vector technology PITTSBURGH–(BUSINESS WIRE)–Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company today announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-19T11:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220719005166\/en\/1516386\/21\/Avista_Logo_Full_Color_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases","datePublished":"2022-07-19T11:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/"},"wordCount":661,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005166\/en\/1516386\/21\/Avista_Logo_Full_Color_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/","url":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/","name":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220719005166\/en\/1516386\/21\/Avista_Logo_Full_Color_RGB.jpg","datePublished":"2022-07-19T11:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220719005166\/en\/1516386\/21\/Avista_Logo_Full_Color_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220719005166\/en\/1516386\/21\/Avista_Logo_Full_Color_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46309"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46309\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}